The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
CHO K1 cell culture process intensification for enhanced production of IgG mAbs
Case study
Biologic therapeutics are inherently complex, but developing them doesn’t have to be. Increased demand for higher product yields requires the optimal use of existing manufacturing capacity. Process intensification is one way biopharma facilities can meet these industry needs by enabling fewer or smaller batches to produce the same amount of product within the same timeframe.
Our recent case study highlights how we developed a process intensification workstream aimed at increasing the titer of CHO processes by 20–50% while meeting the following criteria: 1) no effect on process timelines, 2) maintains comparable product quality attributes, 3) no additional equipment or training required, and 4) compatibility with all existing manufacturing facilities.
Download the case study to see how our CHO K1 cell lines increased titer levels by up to 80% without compromising quality by optimizing process development for specific molecules.
Key highlights include:
- Increased titers from 20% to 100%: Optimized specifically for Rituximab, our intensified process achieves significant yield improvements while maintaining comparable product quality.
- No additional resources needed: The intensified process was successfully implemented within existing manufacturing platforms and facilities without requiring extra equipment or resources.
- Real-world success with Herceptin: A generalized intensified process demonstrated a 20% increase in titers for a Herceptin-expressing cell line, showcasing scalability and broad applicability.
Additional resources
The Science of Cell Line Development for Biologics
Cell line development is critical to biologics manufacturing, influencing efficiency, scalability, and product stability. Advances in CHO-K1 cell line engineering, are driving higher yields, improved gene stability, and faster IND submission pathways.